"Would like to see the results to date compared to nivolumab monotherapy in a similar subset of patients. If no better then Veyonda is worthless. Anyone know?"
It's very complicated. IONIC includes lung, prostate, gastric, pancreatic, nasopharyngeal and metastatic squamous carcinoma.
Across this rather heterogeneous group, Opdivo generally improves outcome in something like 10-90% of cases, which aligns with what we see in IONIC. IONIC was a bit of a hail-mary to see if Veyonda was some sort of universal switch that opens up the gate to Opdivo. We have our answer now and I suspect it will quietly be dropped, as the results are not conclusive and no-one is going to cover the cost to sort out the responsible mechanism for a small subset of responders.
"Would like to see the results to date compared to nivolumab...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.37M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.0¢ | 7.9¢ | $4.146K | 51.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 79733 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 148300 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.9¢ |
Change
0.000 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.9¢ | 2000 | ||
| Last updated 14.36pm 31/05/2024 ? | |||||
| NOX (ASX) Chart |